Coronavirus patient treated with HIV drug saw heart rate drop dangerously low
The patient, in Singapore, was given lopinavir + ritonavir - a drug commonly used in HIV patients because it can stop viruses from being able to reproduce in the body. (Source: the Mail online | Health)
Source: the Mail online | Health - August 24, 2020 Category: Consumer Health News Source Type: news

Lopinavir/Ritonavir COVID-19 Treatment Linked to Bradycardia
FRIDAY, July 17, 2020 -- Lopinavir/ritonavir (LPV/RTV) treatment of COVID-19 is associated with an increased risk for bradycardia, according to a study published online July 9 in Circulation: Arrhythmia and Electrophysiology. Christophe Beyls,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 17, 2020 Category: Pharmaceuticals Source Type: news

WHO Halts Hydroxychloroquine, HIV Drugs in COVID Trials After Failure to Reduce Death WHO Halts Hydroxychloroquine, HIV Drugs in COVID Trials After Failure to Reduce Death
WHO said on Saturday that it was discontinuing its trials of the malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir in hospitalised patients with COVID-19 after they failed to reduce mortality.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 7, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

WHO ending hydroxycholorquine trial for COVID
WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir "produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 5, 2020 Category: Pharmaceuticals Source Type: news

WHO says trials show malaria and HIV drugs don't cut Covid-19 hospital deaths
Hydroxychloroquine and lopinavir/ritonavir not found to help patients in hospitalCoronavirus – latest updatesSee all our coronavirus coverageThe World Health Organization (WHO) said on Saturday that it was discontinuing its trials of the malaria drughydroxychloroquine and combination HIV drug lopinavir/ritonavir for patients in hospital with Covid-19 after they failed to reduce mortality.The setback came as WHO also reported more than 200,000 new cases globally of the disease for the first time in a single day. The US accounted for 53,213 of the total 212,326 new cases recorded on Friday, the WHO said.Continue readin...
Source: Guardian Unlimited Science - July 4, 2020 Category: Science Authors: Reuters Tags: Coronavirus outbreak Medical research World Health Organization World news US news Pharmaceuticals industry Science Infectious diseases Source Type: news

Preliminary trial results find antiviral drug lopinavir/ritonavir does not reduce death in hospitalised patients with COVID-19
The‘RECOVERY’ trial has released preliminary results showing lopinavir/ritonavir, an antiviral drug commonly used to treat HIV, had no significant mortality benefit in hospitalised COVID-19 patients. (Source: Medical Research Council General News)
Source: Medical Research Council General News - July 1, 2020 Category: Research Source Type: news

Antiviral hyped as potential Covid treatment "ineffective", finds major study
Lopinavir-ritonavir showed “no beneficial effect” in hospitalised patients not on ventilators, as per University of Oxford’s Recovery trial – the world’s largest randomised clinical trial of potential Covid treatments. “The data convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the h ospitalised Covid-19 patients,” it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 30, 2020 Category: Pharmaceuticals Source Type: news

Covid-19 treatment hopes dashed as trial of promising HIV drug reveals it does NOT work
Oxford University scientists pulled lopinavir/ritonavir from the RECOVERY Trial today after results showed it had no benefit on people hospitalised with the virus. (Source: the Mail online | Health)
Source: the Mail online | Health - June 29, 2020 Category: Consumer Health News Source Type: news

WHO Says Looking at Interim Trial Data on HIV Drugs to Treat COVID-19 WHO Says Looking at Interim Trial Data on HIV Drugs to Treat COVID-19
Large multi-country trials of the combination HIV drug lopinavir/ritonavir to treat COVID-19 have recruited thousands of patients and WHO is now looking at interim data, the UN agency's chief scientist said on Thursday.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - June 19, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

WHO testing interim data from COVID-19 trial on HIV drugs
The World Health Organization is looking at interim data from its large multi-country trial of the combination of HIV drugs Lopinavir and Ritonavir to treat COVID-19 patients, the UN agency's chief scientist Soumya Swaminathan said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - June 18, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

U.K. Researchers Say They Have Found First Drug that Improves COVID-19 Survival
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients. Results were announced Tuesday and researchers said they would publish them soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care. The drug was given either orally or through an IV. It reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did ...
Source: TIME: Science - June 16, 2020 Category: Science Authors: MARILYNN MARCHIONE /AP Tags: Uncategorized Source Type: news

The Curious Case of Covid-19 in Africa
Eunice G. Kamwendo is an Economist and Strategic Advisor with UNDP Africa in New York. Chaltu Daniel Kalbessa is a UNDP Fellow and Strategic Analyst with UNDP Africa in New York.By Eunice G. Kamwendo and Chaltu Daniel KalbessaNEW YORK, Jun 3 2020 (IPS) With very weak health systems and overall capacity constraints to effectively respond to the deadly coronavirus disease, Africa’s fate against the invisible enemy, was going to be nothing short of catastrophic according to early predictions. Although Africa is yet to reach its peak, many countries are not seeing the exponential growth in case numbers, or in mortality r...
Source: IPS Inter Press Service - Health - June 3, 2020 Category: International Medicine & Public Health Authors: Eunice G. Kamwendo and Chaltu Daniel Kalbessa Tags: Africa Aid Headlines Health Humanitarian Emergencies TerraViva United Nations Source Type: news

Nigeria: What Was Learned in Review of Country's First 32 COVID-19 Cases
[Premium Times] Almost 97 per cent of the first set of COVID-19 patients in Lagos State were treated with lopinavir-ritonavir with no recorded death, a new report has shown. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 20, 2020 Category: African Health Source Type: news

Long-term Safety and Efficacy of OBV/PTV/r + DSV in HCV Long-term Safety and Efficacy of OBV/PTV/r + DSV in HCV
This study reports on the long-term liver disease-associated outcomes for a DAA regimen consisting of ombitasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin for the treatment of chronic HCV.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 14, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

India to test four drugs as part of WHO trial
Potential anti-viral agents remdesivir, chloroquine/hydroxychloroquine, lopinavir-ritonavir and lopinavir-ritonavir with interferon will be evaluated as part of the trial, the Indian Council of Medical Research said on Wednesday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 14, 2020 Category: Pharmaceuticals Source Type: news

India to test four drugs for Covid-19 as part of the WHO solidarity trial
On Wednesday the Indian Council of Medical Research (ICMR) announced that potential anti-viral agents, Remdesivir, Chloroquine/Hydroxychloroquine, Lopinavir-Ritonavir and Lopinavir-Ritonavir with Interferon ( ß1a) will be evaluated as part of the solidarity trial. (Source: The Economic Times)
Source: The Economic Times - May 13, 2020 Category: Consumer Health News Source Type: news

COVID-19 news from Annals of Internal Medicine
(American College of Physicians) Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized with COVID-19 (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 12, 2020 Category: Infectious Diseases Source Type: news

Triple Antiviral Combo Speeds COVID-19 Recovery Triple Antiviral Combo Speeds COVID-19 Recovery
The combination of lopinavir/ritonavir and ribavirin shortened median time to COVID-19 viral negativity by 5 days, according to results of an open-label, randomized phase 2 trial out of Hong Kong.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 11, 2020 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Triple Antiviral Combo May Speed COVID-19 Recovery Triple Antiviral Combo May Speed COVID-19 Recovery
The combination of interferon-beta1, lopinavir/ritonavir, and ribavirin shortened median time to COVID-19 viral negativity by 5 days, according to results of an open-label, randomized phase 2 trial.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - May 11, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Triple Antiviral Therapy Promising for Mild-to-Moderate COVID-19
MONDAY, May 11, 2020 -- For patients with COVID-19, early triple antiviral therapy (lopinavir-ritonavir, ribavirin, and interferon beta-1b) is better than lopinavir-ritonavir for reducing the time to providing a nasopharyngeal swab negative for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2020 Category: Pharmaceuticals Source Type: news

New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomised trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: World Pharma News)
Source: World Pharma News - May 11, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Combination of HIV, hepatitis C, MS drugs might resolve COVID-19 infection
Combination therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin appears to improve symptoms and shorten hospital stays for people with mild to moderate COVID-19. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 9, 2020 Category: Consumer Health News Source Type: news

Antiviral Trio Shows Mettle Against COVID-19
FRIDAY, May 8, 2020 -- A triple whammy of three antiviral drugs shows promise in fighting mild to moderate COVID-19, a new, small study suggests. Two weeks of interferon beta-1b, lopinavir-ritonavir and ribavirin -- along with standard care -- was... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 8, 2020 Category: General Medicine Source Type: news

The Lancet: New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
(The Lancet) A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomized trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 8, 2020 Category: Infectious Diseases Source Type: news

Australian hydroxychloroquine trials continue despite studies showing no benefit to coronavirus patients
Clinical findings of the antimalarial drug have been inconsistent, with one study showing a higher mortality rate when it was administered aloneSign up for Guardian Australia ’s daily coronavirus emailDownload the free Guardian app to get the most important news notificationsThe results of early studies from the US and China, which show disappointing results in the use of an antimalarial drug and an anti-retroviral drug in treating Covid-19, will not impact trials of the drug under way in Australia, researchers say.To date more than 300 clinical trials in humans are under way around the world to investigate treatment...
Source: Guardian Unlimited Science - April 27, 2020 Category: Science Authors: Melissa Davey Tags: Coronavirus outbreak Infectious diseases Science Drugs Health Australia news Medical research Queensland Source Type: news

Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis, MedRxiv, 2020
Conclusions: There is no evidence showing the effectiveness of antiviral agents for children with COVID-19, and the clinical efficacy of existing antiviral agents is still uncertain. We do not suggest clinical routine use of antivirals for COVID-19 in children, with the exception of clinical trials. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 24, 2020 Category: Consumer Health News Source Type: news

Lopinavir/Ritonavir, Umifenovir Ineffective for Mild COVID - 19
Rate of positive - to - negative conversion of SARS - CoV - 2 did not differ for drug therapy versus standard care (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news

Lopinavir/Ritonavir, Umifenovir Ineffective for Mild COVID-19
THURSDAY, April 23, 2020 -- For patients hospitalized with mild/moderate COVID-19, lopinavir/ritonavir (LPV/r) or umifenovir (Arbidol) monotherapy offers little benefit, according to a study published online April 17 in Med. Yueping Li, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2020 Category: Pharmaceuticals Source Type: news

Lopinavir/ritonavir and Arbidol not effective for mild-to-moderate COVID-19 in adults
An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol - antivirals that are used in some countries against HIV-1 and to treat influenza, respectively - as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care. (Source: World Pharma News)
Source: World Pharma News - April 20, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Lopinavir/ritonavir and Arbidol not effective for mild-to-moderate COVID-19 in adults
(Cell Press) An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care. The findings appeared April 17 in Med, a new medical journal published by Cell Press. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 20, 2020 Category: Infectious Diseases Source Type: news

Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19
There is currently no strong evidence of efficacy of Lopinavir/ritonavir in the treatment of COVID-19. The limited studies identified, which overall are subject to methodological flaws. Several ongoing trials of Lopinavir/ritonavir are currenty recruiting. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 14, 2020 Category: Consumer Health News Source Type: news

Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19, CEBM
There is currently no strong evidence of efficacy of Lopinavir/ritonavir in the treatment of COVID-19. The limited studies identified, which overall are subject to methodological flaws. Several ongoing trials of Lopinavir/ritonavir are currenty recruiting. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 14, 2020 Category: Consumer Health News Source Type: news

lopinavir and ritonavir (Kaletra): Potential COVID-19 Drug
Title: lopinavir and ritonavir (Kaletra): Potential COVID-19 DrugCategory: MedicationsCreated: 3/12/2001 12:00:00 AMLast Editorial Review: 4/8/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 8, 2020 Category: Infectious Diseases Source Type: news

Update on treatments and vaccines against COVID-19 under development
At present, potential treatments for COVID-19 undergoing clinical trials are remdesivir (investigational), lopinavir/ritonavir, chloroquine& hydroxychloroquine, systemic interferons and monoclonal antibodies with activity against components of the immune system. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 2, 2020 Category: Consumer Health News Source Type: news

Government invests £20million into six coronavirus research projects
The first major UK trial of the HIV drugs lopinavir-ritonavir is already underway at Oxford University and initial results are expected within three months. (Source: the Mail online | Health)
Source: the Mail online | Health - March 23, 2020 Category: Consumer Health News Source Type: news

Lopinavir-Ritonavir No Benefit in Adults With Severe COVID-19
FRIDAY, March 20, 2020 -- Lopinavir-ritonavir treatment offers no significant benefit over standard care for hospitalized adult patients with severe coronavirus 2019 (COVID-19) infection, according to a study published online March 18 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 20, 2020 Category: Pharmaceuticals Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
Anecdotal, unsubstantiated reports claim that darunavir has antiviral effect against COVID-19Johnson & Johnson has no evidence that darunavir has any effect against SARS-CoV-2, the virus that causes COVID-19Johnson & Johnson is screening its antiviral compounds, including darunavir, to determine potential in vitro effect against SARS-CoV-2We are partnering with multiple organizations to support the development of research programs and fast-track solutions for COVID-19Considering the large public health and humanitarian implications, we are committed to global efforts to care for those affected, contain the current ...
Source: Johnson and Johnson - March 16, 2020 Category: Pharmaceuticals Tags: Corporate Source Type: news

Pharma companies set to supply ARVs for ‘treatment’
Though there is no formal cure discovered to treat the virus, the treatment protocol established in China and confirmation by physicians in Thailand show that a combination of Lopanvir and Ritonavir has worked on patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 4, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
NEW BRUNSWICK, N.J., January 29, 2020 – Johnson & Johnson today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.“J&J has a long-standing comm...
Source: Johnson and Johnson - January 29, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

lopinavir and ritonavir (Kaletra)
Title: lopinavir and ritonavir (Kaletra)Category: MedicationsCreated: 3/12/2001 12:00:00 AMLast Editorial Review: 11/22/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - November 22, 2019 Category: Drugs & Pharmacology Source Type: news

Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)
Title: Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)Category: MedicationsCreated: 8/14/2015 12:00:00 AMLast Editorial Review: 9/4/2019 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - September 4, 2019 Category: Nutrition Source Type: news

ritonavir (Norvir)
Title: ritonavir (Norvir)Category: MedicationsCreated: 12/14/2000 12:00:00 AMLast Editorial Review: 8/16/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 16, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs
The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Technivie (ombitasvir, paritaprevir and ritonavir)
Title: Technivie (ombitasvir, paritaprevir and ritonavir)Category: MedicationsCreated: 10/24/2018 12:00:00 AMLast Editorial Review: 10/24/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 24, 2018 Category: Drugs & Pharmacology Source Type: news

Eight Weeks of Antiviral Therapy for Recent HCV Infection Eight Weeks of Antiviral Therapy for Recent HCV Infection
Is an 8-week therapy of paritaprevir/ritonavir/ombitasvir and dasabuvir + ribavirin as effective as the standard 12-week regimen in individuals with recent HCV infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

OBV/PTV/r +/- DSV in HCV GT4-infected Patients With Severe CKD OBV/PTV/r +/- DSV in HCV GT4-infected Patients With Severe CKD
This study investigated the real-world efficacy of ombitasvir/paritaprevir/ritonavir +/- DSV regimen in HCV genotypes 4 and 1 patients with advanced chronic kidney disease.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Effect of 3D Regimen on HRQoL for Patients With Hepatitis C Effect of 3D Regimen on HRQoL for Patients With Hepatitis C
This study investigated the impact of a RBV-free ombitasvir/paritaprevir/ritonavir + dasabuvir (3D) regimen on health-related quality of life for HCV patients, both during and after treatment.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Protease Inhibitors May Worsen Outcomes for HIV & #43; Heart Failure
WEDNESDAY, Aug. 1, 2018 -- Ritonavir-boosted protease inhibitor (PI) therapy is associated with worse outcomes, including death, in patients with HIV and heart failure, according to a study published in the July 31 issue of the Journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 1, 2018 Category: Pharmaceuticals Source Type: news

Protease inhibitors may increase risk of death in people with HIV and heart failure
Ritonavir-boosted protease inhibitors associated with doubled risk of hospital readmission and cardiovascular death Related items fromOnMedica Stroke rate higher in HIV patients £30 million to tackle antimicrobial resistance Single-dose malaria drug eliminates parasite from liver Ibuprofen not a safe alternative to antibiotics for uncomplicated UTIs Too few women take part in many CVD clinical trials (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 24, 2018 Category: UK Health Source Type: news